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Severe coronavirus disease 2019 (COVID-19) pneumonia associated with cytokine 
storm remains a challenge for clinicians. It is usually complicated by multiple organ 
dysfunction and despite optimal contemporary therapy leads to high mortality.
In this research letter, 3 consecutive patients are presented with severe COVID-19 
pneumonia who between January and March 2021 were successfully treated with tocilizumab 
(a humanized antibody to the soluble interleukin-6 receptor) added to the standard therapy. 
This treatment was approved by the local ethics committee and subsequently all patients 
provided an informed written consent. On admission, all patients were moderately/severely ill
with predominant respiratory failure and markedly elevated C-reactive protein (CRP) 
concentration (Table 1). Therapy with tocilizumab was initiated on day 1 in 2 patients and on 
day 6 in the 3rd one when he developed respiratory collapse requiring high flow oxygen 
therapy. All patients received two doses of tocilizumab and then their CRP concentration 
dropped on average by 71%. Following administration of tocilizumab combined with best 
known therapy, all patients were slowly and continuously improving. They all were 
discharged home in a relatively good condition and at a short-term follow-up are mildly 
symptomatic or asymptomatic.
The decision to use tocilizumab was based on the promising results of randomized 
clinical trials (RCTs) published since March 2020 [1–10]. The largest and most recent study 
with the most spectacular outcomes is the RECOVERY trial [1]. Its results have only been 
published as a preprint to date. This trial included 4,116 participants receiving invasive 
ventilation (14%), non-invasive ventilation (41%) or usual oxygen therapy (45%). All 
enrolled patients had oxygen saturation < 92% and CRP concentration > 75 mg/dL. Median 
CRP in the RECOVERY trial was 143 [interquartile range 107–204] mg/L which is similar to 
our patients. Additionally, 82% of patients in the REVOVERY trial received systemic 
corticosteroids at randomization. The primary endpoint (all-cause 28-day mortality) was 
substantially reduced in the tocilizumab on top of standard care vs. standard care alone group 
(29% vs. 33%, p = 0.007), with consistent results in all predefined subgroups. Significant 
reductions in terms of secondary endpoints were also achieved in tocilizumab-treated patients 
(discharge from hospital alive within 28 days [54% vs. 47%], composite outcome of invasive 
mechanical ventilation or death [33% vs. 38%] and use of hemodialysis or hemofiltration [5%
vs 7%]). Tocilizumab benefits were observed regardless of the level of respiratory support and
were additional to the benefits of systemic corticosteroids, another class of anti-inflammatory 
agents. Also, the results of two moderate size RCTs indicated clinical benefits of tocilizumab. 
In the REMAP-CAP trial conducted in critically ill patients with COVID-19 pneumonia 
receiving organ support in intensive care units, treatment with the interleukin-6 receptor 
antagonist (tocilizumab [n = 353] or sarilumab [n = 48]) when compared with the control 
group (n = 402) improved clinical outcomes, including 90-day survival [2]. Similarly, the 
EMPACTA trial demonstrated superiority of tocilizumab (n = 249) over placebo (n = 128) on 
the primary composite endpoint of mechanical ventilation or death by day 28, but without any
improvement in mortality [3]. This study included only patients who did not require 
mechanical ventilation at randomization. Importantly, several small/moderate size (all largely 
underpowered for assessment of hard clinical endpoints) RCTs indicated a neutral effect of 
tocilizumab on clinical outcomes [4–7], with some minor benefits seen in the CORIMUNO-
19 study [5]. On the other hand, the TOCIBRAS trial was stopped early after inclusion of 129 
participants due to a signal of increased mortality at 15 days related to tocilizumab therapy 
(11/65 [17%] vs. 2/64 [3%]) [8]. This observation may be a chance to find out when, 
considering the very low mortality in the standard care alone group. In all of the RCTs 
discussed above , adverse events were not more frequent in the tocilizumab vs. 
placebo/standard care group [1–8]. Finally, an updated meta-analysis of all available RCTs 
performed by the ROCOVERY investigators shows all-cause mortality benefit in patients 
hospitalized for COVID-19 pneumonia and treated with tocilizumab added to usual care when
compared with the usual care alone group (relative risk 0.87; 95% confidence interval 0.79–
0.96; p = 0.005), with a substantial heterogeneity among the included trials [1]. Furthermore, 
it is suggested that tocilizumab may exert an additive beneficial effect in remdesivir-treated 
patients [9], as was used in the present case series.
Based on the totality of the research evidence [10] and our clinical experience, we 
believe that tocilizumab is well tolerated and may be beneficial on top of standard therapy if 
early initiated in patients with COVID-19 pneumonia and both enhanced inflammatory 
response and a large extent of the involved lung tissue. However, further RCTs are necessary 
to define best tocilizumab responders.
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Table 1. Characteristics of patients severe COVID-19 pneumonia and respiratory failure treated with tocilizumab.
Patient 1 Patient 2 Patient 3
Demographic data
Age [years] 61 61 70
Gender Male Female Male
Clinical characteristics and course, including respiratory status and support
Body mass index [kg/m2] 25 34 27
Comorbidities Bronchial asthma, acute 
kidney injury (stage 1 
according to KDIGO)
Hypertension, paroxysmal atrial 
fibrillation, history of pulmonary
embolism, bronchial asthma, 
status post colon cancer surgery
Type 2 diabetes mellitus, 
diabetic neuropathy
Duration of symptom onset to 
hospital admission [days]
7 7 12
Clinical status on 7 level ordinal 
scale on hospital admission
4 4 4
Extent of the involved lung tissue on 
CT [%]
27* 78 75
Oxygen saturation on admission [%] 90 then deterioration to 75 
on day 3
80 70
Minimal arterial pO2 [mmHg] 49.5 45.1 50.3
Respiratory support High flow oxygen through 
a nasal cannula [up to 60 
L/min through 16 days]
Supplemental oxygen through a 
face mask [up to 17 L/min 
through 11 days]
Supplemental oxygen through 
a face mask [up to 17 L/min 
through 10 days]
Blood culture All negative (obtained twice in all patients)
Laboratory measurements on hospital admission
Lymphocyte count [G/L] 0.35 0.75 0.95
CRP concentration [mg/L] 137.1 209.7 169
Procalcitonin concentration [ng/mL] 0.28 0.2 0.22
D-dimer concentration [ng/mL] 35200 768 Not available
Creatinine concentration [mg/dL] 1.44 (after patient 
hydration a decrease to 
0.94 0.94
0.83)
Lactate dehydrogenase activity [U/L] 720 454 Not available
Cardiac troponin T Negative Mildly elevated (0.055 ng/L) Negative
Pharmacotherapy during hospitalization
Treatment with dexamethasone Yes (6 mg IV once daily) Yes (6 mg IV once daily) Yes (6 mg IV once daily)
Treatment with remdesivir Yes (initiated on day 3) Yes (initiated on day 3) Yes (initiated on day 1)
Anticoagulation Prophylactic dose of 
enoxaparin
Rivaroxaban 20 mg/day Prophylactic dose of 
enoxaparin
Treatment with tocilizumab Initiated on day 6 at the 
dose of 600 mg IV which 
was repeated on day 7
Initiated on day 1 at the dose of 
720 mg IV which was repeated 
on day 2
Initiated on day 2 at the dose of
640 mg IV which was repeated
on day 3
Effect of tocilizumab administration 
on CRP concentration
After 2nd dose a decrease 
from 137 to 56 mg/L on 
the 2nd day
After 2nd dose a decrease from 
209 to 40 mg/L on the 3rd day
After 2nd dose a decrease from 
169 to 58 mg/L on the 3rd day
Antibiotic therapy Ceftriaxone initiated on 
admission then on day 2 
changed for piperacillin 
/tazobactam then on day 8 
changed for meropenem 
for 7 days
Ceftriaxone initiated on 
admission and continued for 10 
days
Ceftriaxone initiated on 
admission and continued for 10
days
Hospital discharge and follow-up
Length of hospitalization [days] 28 13 14
Clinical status at the end of 
hospitalization
Discharged in a relatively good condition with the need of temporal low flow oxygen 
supplementation at home 
Length of follow-up [days] 53 26 31
Clinical status at the end of follow-
up
Fully recovered without 
any respiratory failure
The need of temporary low flow oxygen supplementation at home
*No control CT was performed after deterioration of the respiratory status as the patients was treated with high flow oxygen therapy and we were
not able to transport him safely without tracheal intubation; CRP — C-reactive protein; CT — computed tomography; KDIGO — Kidney 
Disease: Improving Outcomes; pO2 — partial pressure of oxygen; SpO2 — oxygen saturation
